Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy

References

• AlmirallJBolibarIVidalJEpidemiology of community-acquired pneumonia in adults: a population-based studyEur Respir J200015475776310780770
   PubMed Web of Science ®Google Scholar
• GutierrezFMasiaMRodriguezJCEpidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of SpainClin Microbiol Infect2005111078880016153252
   PubMed Web of Science ®Google Scholar
• LohLCKhooSKQuahSYAdult community-acquired pneumonia in Malaysia: prediction of mortality from severity assessment on admissionRespirology20049337938615363012
   PubMed Web of Science ®Google Scholar
• O’MearaESWhiteMSiscovickDSLylesMFKullerLHHospitalization for pneumonia in the Cardiovascular Health Study: incidence, mortality, and influence on longer-term survivalJ Am Geriatr Soc20055371108111616108926
   PubMed Web of Science ®Google Scholar
• GutiérrezFMasiáMMireteCThe influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogensJ Infect200653316617416375972
   PubMed Web of Science ®Google Scholar
• KaplanVAngusDCCommunity-acquired pneumonia in the elderlyCrit Care Clin200319472974814601717
   PubMed Web of Science ®Google Scholar
• ViegiGPistelliRCazzolaMEpidemiological survey on incidence and treatment of community acquired pneumonia in ItalyRespir Med20061001465516046113
   PubMed Web of Science ®Google Scholar
• ColiceGLMorleyMAAscheCBirnbaumHGTreatment costs of community-acquired pneumonia in an employed populationChest200412562140214515189934
   PubMed Web of Science ®Google Scholar
• NiedermanMSMandellLAAnzuetoAGuidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and preventionAm J Respir Crit Care Med200116371730175411401897
   PubMed Web of Science ®Google Scholar
• KollefMHShorrATabakYPGuptaVLiuLZJohannesRSEpidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumoniaChest200512863854386216354854
   PubMed Web of Science ®Google Scholar
• BodiMRodriguezASole-ViolanJAntibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survivalClin Infect Dis200541121709171616288392
   PubMed Web of Science ®Google Scholar
• TejerinaEFrutos-VivarFRestrepoMIPrognosis factors and outcome of community-acquired pneumonia needing mechanical ventilationJ Crit Care200520323023816253791
   PubMed Web of Science ®Google Scholar
• WilsonPAFergusonJSevere community-acquired pneumonia: an Australian perspectiveIntern Med J2005351269970516313544
   PubMed Web of Science ®Google Scholar
• WoodheadMWelchCAHarrisonDABellinganGAyresJGCommunity-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme DatabaseCrit Care200610Suppl 2S116934135
   PubMed Web of Science ®Google Scholar
• FileTMJrClinical implications and treatment of multiresistant Streptococcus pneumoniae pneumoniaClin Microbiol Infect200612Suppl 3314116669927
   PubMed Web of Science ®Google Scholar
• LauderdaleTLChangFYBenRJEtiology of community acquired pneumonia among adult patients requiring hospitalization in TaiwanRespir. Med20059991079108616085210
   PubMed Web of Science ®Google Scholar
• LeesikHAniUJuhaniAAltrajaAMicrobial pathogens of adult community-acquired pneumonia in Southern EstoniaMedicina (Kaunas)200642538439416778466
   PubMedGoogle Scholar
• LunaCMFamigliettiAAbsiRCommunity-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in ArgentinaChest200011851344135411083685
   PubMed Web of Science ®Google Scholar
• HuangHHZhangYYXiuQYCommunity-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patientsEur J Clin Microbiol Infect Dis200625636937416767484
   PubMed Web of Science ®Google Scholar
• SaitoAKohnoSMatsushimaTProspective multicenter study of the causative organisms of community-acquired pneumonia in adults in JapanJ Infect Chemother2006122636916648944
   PubMedGoogle Scholar
• ThibodeauKPVieraAJAtypical pathogens and challenges in community-acquired pneumoniaAm Fam Physician20046971699170615086042
   PubMed Web of Science ®Google Scholar
• WoodheadMCommunity-acquired pneumonia in Europe: causative pathogens and resistance patternsEur Respir J Suppl20023620s27s12168744
   PubMedGoogle Scholar
• FileTMJrGarauJBlasiFGuidelines for empiric antimicrobial prescribing in community-acquired pneumoniaChest200412551888190115136404
   PubMed Web of Science ®Google Scholar
• MandellLAWunderinkRGAnzuetoAInfectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adultsClin Infect Dis200744Suppl 2S27S7217278083
   PubMed Web of Science ®Google Scholar
• WoodheadMBlasiFEwigSGuidelines for the management of adult lower respiratory tract infectionsEur Respir J20052661138118016319346
   PubMed Web of Science ®Google Scholar
• DoernGVRichterSSMillerAAntimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?Clin Infect Dis200541213914815983908
   PubMed Web of Science ®Google Scholar
• BonofiglioLOjedaMIde MierCPhenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospitalInt J Antimicrob Agents200525326026315737523
   PubMed Web of Science ®Google Scholar
• FelminghamDComparative antimicrobial susceptibility of respiratory tract pathogensChemotherapy200450Suppl 131015319548
   PubMed Web of Science ®Google Scholar
• FullerJDMcGeerALowDEDrug-resistant pneumococcal pneumonia: clinical relevance and approach to managementEur J Clin Microbiol Infect Dis2005241278078816344922
   PubMed Web of Science ®Google Scholar
• ReinertRRReinertSvan der LindenMCilMYAl-LahhamAAppelbaumPAntimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003Antimicrob Agents Chemother20054972903291315980367
   PubMed Web of Science ®Google Scholar
• JonesRNFritscheTRSaderHSStilwellMGActivity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC valuesDiagn Microbiol Infect Dis200758191717408903
   PubMed Web of Science ®Google Scholar
• BrownSDRybakMJAntimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001–2002, as part of the PRO-TEKT US studyJ Antimicrob Chemother200454Suppl 1i7i1515265831
   PubMed Web of Science ®Google Scholar
• DoernGVBrownSDAntimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000–2001J Infect2004481566514667792
   PubMed Web of Science ®Google Scholar
• HobanDWaitesKFelminghamDAntimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999–2000: findings of the PROTEKT surveillance studyDiagn Microbiol Infect Dis200345425125912729995
   PubMed Web of Science ®Google Scholar
• KarlowskyJAThornsberryCJonesMEFactors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998–2002)Clin Infect Dis200336896397012684907
   PubMed Web of Science ®Google Scholar
• WangJCDNA topoisomerasesAnnu Rev Biochem1996656356928811192
   PubMed Web of Science ®Google Scholar
• WangJCA journey in the world of DNA rings and beyondAnnu Rev Biochem200978315419489720
   PubMed Web of Science ®Google Scholar
• HubandMDCohenMAZurackMIn vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groupsAntimicrob Agents Chemother20075141191120117261623
   PubMed Web of Science ®Google Scholar
• CroomKFGoaKLLevofloxacin: a review of its use in the treatment of bacterial infections in the United StatesDrugs200363242769280214664657
   PubMed Web of Science ®Google Scholar
• KeatingGMScottLJMoxifloxacin: a review of its use in the management of bacterial infectionsDrugs200464202347237715456331
   PubMed Web of Science ®Google Scholar
• Levaquin® (levofloxacin tablets, oral solution, injection): US prescribing informationRaritan (NJ)Ortho-McNeil Pharmaceutical, Inc82009
   Google Scholar
• HurstMLambHMScottLJFiggittDPLevofloxacin: an updated review of its use in the treatment of bacterial infectionsDrugs200262142127216712269858
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards InstituteMethods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard – seventh editionClinical and Laboratory Standards Institute Document M7-A7Wayne, PAClinical and Laboratory Standards Institute12006262
   Google Scholar
• GordonKASaderHSJonesRNContemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United StatesDiagn Microbiol Infect Dis200347137738312967754
   PubMed Web of Science ®Google Scholar
• FritscheTRSaderHSJonesRNPotency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999–2004)Diagn Microbiol Infect Dis2007581192617383139
   PubMed Web of Science ®Google Scholar
• GoffDADowzickyMJPrevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobialJ Med Microbiol200756Pt 91189119317761482
   PubMed Web of Science ®Google Scholar
• BiedenbachDJTolemanMAWalshTRJonesRNCharacterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997–2004)Diagn Microbiol Infect Dis200655211912716530373
   PubMed Web of Science ®Google Scholar
• NiliusAMShenLLHensey-RudloffDIn vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinoloneAntimicrob Agents Chemother200347103260326914506039
   PubMed Web of Science ®Google Scholar
• JacobsMRFelminghamDAppelbaumPCGrunebergRNAlexander Project GroupThe Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agentsJ Antimicrob Chemother200352222924612865398
   PubMed Web of Science ®Google Scholar
• SorianoFGranizoJJCoronelPAntimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE projectInt J Antimicrob Agents200423329629915164972
   PubMed Web of Science ®Google Scholar
• HansenGTBlondeauJMComparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogensJ. Chemother200517548449216323436
   PubMed Web of Science ®Google Scholar
• DeshpandeLMDiekemaDJJonesRNComparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitalsDiagn Microbiol Infect Dis1999351818810529885
   PubMed Web of Science ®Google Scholar
• RolstonKVFrisbee-HumeSLeBlancBMStreeterHHoDHAntimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756): compared to other quinolones, against clinical isolates from cancer patientsDiagn Microbiol Infect Dis200244218719412458127
   PubMed Web of Science ®Google Scholar
• ThornsberryCSahmDFKellyLJRegional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000Clin Infect Dis200234Suppl 1S4S1611810606
   PubMed Web of Science ®Google Scholar
• KarlowskyJAThornsberryCCritchleyIASusceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000–2001 and 2001–2002 TRUST studies in the United StatesAntimicrob Agents Chemother20034761790179712760850
   PubMed Web of Science ®Google Scholar
• ZhanelGGHisanagaTLLaingNMAntibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)Int J Antimicrob Agents200627646847516713191
   PubMed Web of Science ®Google Scholar
• CritchleyIAJonesMEHeinzePDIn vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and EuropeClin Microbiol Infect20028421422112047413
   PubMed Web of Science ®Google Scholar
• RoblinPMReznikTKutlinAHammerschlagMRIn vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648): ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniaeAntimicrob Agents Chemother20034731135113612604555
   PubMed Web of Science ®Google Scholar
• KohlhoffSARoblinPMReznikTHawserSIslamKHammerschlagMRIn vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniaeAntimicrob Agents Chemother20044851885188615105151
   PubMed Web of Science ®Google Scholar
• HammerschlagMRRoblinPMThe in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniaeJ Antimicrob Chemother200454128128215190026
   PubMed Web of Science ®Google Scholar
• DuboisJSt-PierreCComparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella sppJ Antimicrob Chemother200045Suppl 1414610824031
   PubMed Web of Science ®Google Scholar
• StoutJESensKMietznerSObmanAYuVLComparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testingInt J Antimicrob Agents200525430230715784309
   PubMed Web of Science ®Google Scholar
• WaitesKBCrabbDMBingXDuffyLBIn vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmasAntimicrob Agents Chemother200347116116512499185
   PubMed Web of Science ®Google Scholar
• WaitesKBCrabbDMDuffyLBComparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmasAntimicrob Agents Chemother200852103776377818663020
   PubMed Web of Science ®Google Scholar
• DuffyLBCrabbDMBingXWaitesKBBactericidal activity of levofloxacin against Mycoplasma pneumoniaeJ Antimicrob Chemother200352352752812888583
   PubMed Web of Science ®Google Scholar
• DunbarLMWunderinkRGHabibMPHigh-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigmClin Infect Dis200337675276012955634
   PubMed Web of Science ®Google Scholar
• WaitesKBCrabbDMDuffyLBComparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmasAntimicrob Agents Chemother200347123973397514638513
   PubMed Web of Science ®Google Scholar
• FelminghamDFeldmanCHryniewiczWSurveillance of resistance in bacteria causing community-acquired respiratory tract infectionsClin Microbiol Infect20028Suppl 2124212427206
   PubMed Web of Science ®Google Scholar
• CantonRMorosiniMEnrightMCMorrisseyIWorldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programmeJ Antimicrob Chemother200352694495214585861
   PubMed Web of Science ®Google Scholar
• HigginsPGFluitACMilatovicDVerhoefJSchmitzFJMutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosaInt J Antimicrob. Agents200321540941312727072
   PubMed Web of Science ®Google Scholar
• DerykeCADuXNicolauDPEvaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniaeJ Antimicrob Chemother200658360160916857688
   PubMed Web of Science ®Google Scholar
• LaPlanteKLRybakMJTsujiBLodiseTPKaatzGWFluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacinAntimicrob Agents Chemother20075141315132017296740
   PubMed Web of Science ®Google Scholar
• SahmDFBenningerMSEvangelistaATYeeYCThornsberryCBrownNPAntimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001–2005)Otolaryngol Head Neck Surg2007136338538917321864
   PubMed Web of Science ®Google Scholar
• WestMBoulangerBRFogartyCLevofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label studyClin Ther200325248550612749509
   PubMed Web of Science ®Google Scholar
• ChowATFowlerCWilliamsRRMorganNKaminskiSNatarajanJSafety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteersAntimicrob Agents Chemother20014572122212511408234
   PubMed Web of Science ®Google Scholar
• ChienSCWongFAFowlerCLDouble-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteersAntimicrob Agents Chemother19984248858889559801
   PubMed Web of Science ®Google Scholar
• SteinGESchooleySLNicolauDPUrinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coliInt J Antimicrob Agents200832432032518715762
   PubMed Web of Science ®Google Scholar
• GotfriedMHDanzigerLHRodvoldKASteady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjectsChest200111941114112211296178
   PubMed Web of Science ®Google Scholar
• RodvoldKADanzigerLHGotfriedMHSteady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adultsAntimicrob Agents Chemother20034782450245712878504
   PubMed Web of Science ®Google Scholar
• CapitanoBMattoesHMShoreESteady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adultsChest2004125396597315006955
   PubMed Web of Science ®Google Scholar
• ConteJEJrGoldenJAMcIverMLittleEZurlindenEIntrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary diseaseInt J Antimicrob Agents200730542242717716873
   PubMed Web of Science ®Google Scholar
• DrusanoGLPrestonSLGotfriedMHDanzigerLHRodvoldKALevofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulationAntimicrob Agents Chemother200246258658911796385
   PubMed Web of Science ®Google Scholar
• PeaFMarioniGPavanFPenetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dosePharmacol Res20074551384117092740
   PubMed Web of Science ®Google Scholar
• GarraffoRLavrutTDurantJIn vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophilsClin Drug Investig20052510643650
   Web of Science ®Google Scholar
• PooleMAnonJPagliaMXiangJKhashabMKahnJA trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitisOtolaryngol Head Neck Surg20061341101716399173
   PubMed Web of Science ®Google Scholar
• PetersonJKaulSKhashabMFisherACKahnJBA double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritisUrology2008711172218242357
   PubMed Web of Science ®Google Scholar
• KlausnerHABrownPPetersonJA trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritisCurr Med Res Opin200723112637264517880755
   PubMed Web of Science ®Google Scholar
• DunbarLMKhashabMMKahnJBZadeikisNXiangJXTennenbergAMEfficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogensCurr Med Res Opin200420455556315119993
   PubMed Web of Science ®Google Scholar
• ShorrAFZadeikisNXiangJXTennenbergAMWes ElyEA multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥65 years with community-acquired pneumoniaClin Ther20052781251125916199249
   PubMed Web of Science ®Google Scholar
• FileTMJrMilkovichGTennenbergAMXiangJXKhashabMMZadeikisNClinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumoniaCurr Med Res Opin20042091473148115383197
   PubMed Web of Science ®Google Scholar
• ShorrAFKhashabMMXiangJXTennenbergAMKahnJBLevofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patientsRespir Med2006100122129213616730170
   PubMed Web of Science ®Google Scholar
• Levofloxacin revisitedMed Lett Drugs Ther20115313685521738109
   PubMed Web of Science ®Google Scholar
• KhashabMMXiangJKahnJBComparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infectionsCurr Med Res Opin200622101997200617022859
   PubMed Web of Science ®Google Scholar
• YeeYCEvangelistaATObot-TuckerMFive-year surveillance (2003–2007) of anti-pneumococcal activity of oral agents recommended for the empirical treatment of community-acquired pneumonia (CAP) in adults [Abstract No C2204]47th Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, ILSep 17–20, 2007
   Google Scholar